טוען...
Add-on perampanel in Lance–Adams syndrome
Perampanel (PER) is the first-in-class selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist that has been licensed and marketed as antiepileptic drug (AED) indicated for patients with partial-onset and primary generalized tonic–clonic seizures. A...
שמור ב:
| הוצא לאור ב: | Epilepsy Behav Case Rep |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4939387/ https://ncbi.nlm.nih.gov/pubmed/27437182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebcr.2016.05.001 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|